Skip to content
DataLookout
Menu

NCT07885709

MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Pathological complete response (pCR) rate in the treatment-escalation population
Timeframe: At the time of definitive surgery, approximately 13 to 18 weeks after initiation of neoadjuvant therapy

Secondary (8)

Major pathological response (MPR) rate in the treatment-escalation population
Pathological complete response (pCR) rate in the intention-to-treat (ITT) population
Major pathological response (MPR) rate in the intention-to-treat (ITT) population
2-year event-free survival (EFS) rate in the treatment-escalation and ITT populations
2-year overall survival (OS) rate in the treatment-escalation and ITT populations
Show 3 moreShow less
Objective response rate (ORR) in the treatment-escalation and ITT populations
Disease control rate (DCR) in the treatment-escalation and ITT populations
Incidence and severity of treatment-related adverse events (TRAEs)

Arms and interventions

ctDNA-MRD and imaging-guided dynamic neoadjuvant therapyExperimental

All participants initially receive two 21-day cycles of one PD-1 inhibitor (nivolumab, pembrolizumab, toripalimab, or tislelizumab) plus platinum-based doublet chemotherapy (nab-paclitaxel/carboplatin for squamous; pemetrexed/carboplatin for non-squamous histology). After two cycles, ctDNA-MRD testing and radiological assessment (RECIST 1.1) guide treatment: patients with ctDNA non-clearance and stable disease receive an intensified four-drug regimen (PD-1 inhibitor + anlotinib + nab-paclitaxel + carboplatin) for cycles 3-4, non-squamous patients switching from pemetrexed to nab-paclitaxel; all others (ctDNA clearance, or CR/PR) continue the original regimen. Upon completion of neoadjuvant therapy, patients deemed resectable by a multidisciplinary team undergo definitive surgery.

Drugs: PD-1 inhibitor, Carboplatin, Nab-paclitaxel, Pemetrexed, Anlotinib

Sites

1 site in 1 country

  • Peking University People's HospitalBeijing, Beijing Municipality, China